DDX43
DDX43 (Probable ATP-dependent RNA helicase DDX43) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Uveal melanoma.
Overview
UniProt has no function text for Q9NXZ2; HGNC names it "DEAD-box helicase 43".
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Trametinib, Mirdametinib and Selumetinib.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · DDX43 (Probable ATP-dependent RNA helicase DDX43) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Uveal melanoma.
- 1 · What it is
DDX43 (Probable ATP-dependent RNA helicase DDX43) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Uveal melanoma.
- 2 · What goes wrong in cancer
UniProt has no function text for Q9NXZ2; HGNC names it "DEAD-box helicase 43". Locus 6q13 (HGNC).
- 3 · How drugs use it
No product in this corpus aims at DDX43 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:18677 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NXZ2 (protein name, function text, keywords and locations (REST API)); CIViC gene DDX43 (1 evidence items, 0 assertions, 1 variants; diseases: Uveal Melanoma (GraphQL API, CC0))
Biology
UniProt has no function text for Q9NXZ2; HGNC names it "DEAD-box helicase 43". Locus 6q13 (HGNC).
- Uveal melanoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"DDX43" OR ABSTRACT:"DDX43" OR TITLE:"DEAD-box helicase 43" OR ABSTRACT:"DEAD-box helicase 43" OR TITLE:"Probable ATP-dependent RNA helicase DDX43" OR ABSTRACT:"Probable ATP-dependent RNA helicase DDX43" OR TITLE:"DKFZp434H2114" OR ABSTRACT:"DKFZp434H2114" OR TITLE:"CT13" OR ABSTRACT:"CT13") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DDX43, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCYSLTR2
Shares Uveal melanoma, CIViC.
- TargetMBD4
Shares Uveal melanoma, CIViC.
- TargetGNA11
Shares Uveal melanoma, CIViC.
- TargetEIF1AX
Shares Uveal melanoma, CIViC.
- TargetGNAQ
Shares Uveal melanoma, CIViC.